Purchase this article with an account.
U. K. Nair, A. Bui, R. Roe, A. D. Fu, J. M. Jumper, R. N. Johnson, H. R. McDonald, E. T. Cunningham, Jr.; Blood Pressure Measurements Following Intravitreal Ranibizumab. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4577. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of intravitreal Ranibizumab on blood pressure in patients with neovascular age-related macular degeneration (AMD).
Retrospective chart review was conducted for consecutive patients (n=71) who received intravitreal Ranibizumab to treat neovascular AMD had blood pressure measured prior to intravitreal injection and at monthly follow up visits.
Follow up ranged from 0 to 10 months, with a mean of 3.4 and a median of 4 months. 63% of patients had a history of systemic hypertension and 4% had a history of stroke prior to receiving Ranibizumab. Average pre-injection systolic, diastolic, and mean arterial blood pressures (MAP) were 132, 73.30, and 92.88 respectively. Average post-injection systolic, diastolic and MAP at one month were 131.80, 71, and 94.95. One patient (1.4%) had a stroke between her second and third visits. Another patient was found to have a pigment epithelial tear. None of these patients experienced a change in blood pressure following their first injection. No other ocular or systemic adverse events were noted.
Ranibizumab does not appear to affect systemic blood pressure in the short term.
This PDF is available to Subscribers Only